Advertisement
RVTY vs WAT
Which Stock Would AI Choose? Revvity (RVTY) vs. Waters Corporation (WAT) Stock Comparison
Key Takeaways
- Revvity (RVTY) is a diversified diagnostics and life-sciences company, while Waters Corporation (WAT) is a specialist in analytical instruments such as mass spectrometry and liquid chromatography.
- In recent market activity, RVTY has posted notably stronger momentum, including a multi-session winning streak and a sharper three-month gain than WAT.
- WAT is integrating a transformative acquisition (BD Biosciences and Diagnostic Solutions), which has lifted reported revenue and prompted management to raise its full-year guidance.
- RVTY trades at a premium valuation relative to its earnings, while WAT carries elevated integration and balance-sheet risk from its recent deal.
- Tickeron AI Verdict: Based on trend consistency, relative performance, and market positioning, Tickeron's AI currently favors RVTY over WAT.
- For more detail, explore RVTY Major News, RVTY Today's Price Move, WAT Major News, and WAT Today's Price Move.
- To see which strategies are performing best right now, explore Trending AI Robots.
Introduction
Revvity and Waters Corporation are two prominent names in the life-sciences and analytical-instrumentation industry, yet they pursue different strategies. RVTY operates across diagnostics and life-sciences tools, while WAT is anchored in precision measurement instruments and, more recently, a major push into biosciences and diagnostics through acquisition. Comparing these two stocks is relevant for investors and traders weighing a diversified, diagnostics-heavy operator against a specialized instruments business undergoing rapid transformation. Their recent relative performance, valuation profiles, and catalysts make this a timely side-by-side evaluation of momentum, growth drivers, and market positioning.
RVTY Overview and Recent Performance
Revvity, formerly PerkinElmer, rebranded in 2023 and now operates through two core segments: diagnostics and life sciences. With roughly 2025 revenue of $2.9 billion and about 11,000 employees, the company provides instruments, reagents, and software serving pharmaceutical, biotech, diagnostic-lab, academic, and government customers worldwide. Recent quarters have highlighted Diagnostics strength, including reproductive health and newborn screening, alongside a divestiture of its China immunodiagnostics (IDX) business to sharpen portfolio focus.
In recent market activity, RVTY has shown considerable momentum, including a seven-session winning streak that pushed shares toward their highest levels of the past year. The stock has outpaced the broader market substantially over both the three-month and year-to-date periods, and the company recently launched an AI-first workflow tool, Signals LabGistics, which has added an artificial-intelligence narrative to its software offering. That strength, however, has left the shares trading at a premium valuation, and several analyst price targets now sit below the prevailing share price, reflecting debate over how much future growth is already reflected in the stock.
WAT Overview and Recent Performance
Waters Corporation is a global specialist in analytical workflow solutions, best known for its liquid chromatography and mass spectrometry systems used across pharmaceutical, industrial, and academic settings. The company's profile changed materially in early 2026 when it completed the acquisition of BD's Biosciences and Diagnostic Solutions businesses, transforming Waters into a larger, more diversified life-sciences and diagnostics player.
In recent weeks, WAT has advanced steadily, and management raised its full-year guidance after the acquired businesses performed ahead of expectations. Strong pharma demand—including applications tied to GLP-1 drug manufacturing and PFAS (per- and polyfluoroalkyl substances) testing—has supported organic growth, and the company has begun capturing pricing and cost-synergy benefits from the integration. At the same time, the deal has expanded the balance sheet and introduced integration complexity, and some insider selling has been reported. Overall, WAT presents a fundamentally strong but more complex and leveraged profile than RVTY.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's strongest-performing automated trading strategies. Tickeron maintains hundreds of AI trading bots that trade thousands of different tickers, but only those best suited to current market conditions earn a place in this featured section. These bots span a wide range of trading styles, timeframes, strategies, and performance statistics, each targeting its own set of stocks. For traders and investors comparing names like RVTY and WAT, the page offers a useful way to observe which algorithmic approaches are aligning with prevailing market trends. Explore Trending AI Robots to see which strategies are currently leading the platform.
Head-to-Head Comparison
The two companies differ most sharply in business model and growth strategy. RVTY blends a recurring diagnostics franchise with life-sciences tools and informatics, giving it a relatively diversified, annuity-like revenue base. WAT is more concentrated in instruments and consumables but has expanded aggressively into biosciences and diagnostics through acquisition, a move that brings scale and cross-selling potential along with integration risk.
On momentum, RVTY has been the stronger performer recently, with a more persistent uptrend and a larger three-month advance. WAT has risen as well, but its gains have been more moderate. On catalysts, WAT holds a clearer near-term fundamental story through acquisition synergies and raised guidance, whereas RVTY leans more on diagnostics resilience and its emerging AI software narrative. Valuation is another contrast: RVTY trades at a notably higher earnings multiple, while WAT carries a larger debt load and post-deal complexity. Risk profiles differ accordingly, with RVTY exposed to valuation sensitivity and WAT exposed to execution and integration risk.
Tickeron AI Verdict
Weighing trend consistency, relative performance, and market positioning, Tickeron's AI currently leans toward RVTY. The stock's persistent uptrend, multi-session winning streak, and stronger three-month and year-to-date outperformance suggest more reliable momentum than WAT at this stage. While WAT offers compelling fundamental catalysts from its acquisition and raised guidance, its trend has been comparatively less consistent. The AI's preference is probabilistic rather than definitive: if WAT's integration momentum accelerates or RVTY's valuation premium contracts, the relative picture could shift. Based on currently observable signals, RVTY is the favored ticker.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RVTY is a Hold and WAT is a Hold.
RVTY's RSI Indicator leaves overbought zone
The 10-day RSI Oscillator for RVTY moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 instances where the indicator moved out of the overbought zone. In 24 of the 31 cases the stock moved lower in the days that followed. This puts the odds of a move down at 77%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 68 cases where RVTY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.
The Moving Average Convergence Divergence Histogram (MACD) for RVTY turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 33 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RVTY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
RVTY broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on RVTY as a result. In 61 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
Following a +2.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where RVTY advanced for three days, in 200 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 122 of 181 cases where RVTY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 3 (best 1 - 100 worst), indicating outstanding price growth. RVTY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.340) is normal, around the industry mean (65.876). P/E Ratio (72.885) is within average values for comparable stocks, (3.542). Projected Growth (PEG Ratio) (0.734) is also within normal values, averaging (3.473). Dividend Yield (0.002) settles around the average of (0.002) among similar stocks. P/S Ratio (5.656) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RVTY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
WAT in downward trend: price may drop because broke its higher Bollinger Band on October 27, 2026
WAT broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 38 similar instances where the stock broke above the upper band. In 25 of the 38 cases the stock fell afterwards. This puts the odds of success at 66%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for WAT moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 21 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 70 cases where WAT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 63%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on WAT as a result. In 60 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for WAT just turned positive on October 21, 2026. Looking at past instances where WAT's MACD turned positive, the stock continued to rise in 28 of 45 cases over the following month. The odds of a continued upward trend are 62%.
Following a +2.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where WAT advanced for three days, in 179 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 118 of 207 cases where WAT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 10 (best 1 - 100 worst), indicating outstanding price growth. WAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock slightly better than average.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.907) is normal, around the industry mean (65.876). WAT has a moderately high P/E Ratio (112.947) as compared to the industry average of (3.542). Projected Growth (PEG Ratio) (1.649) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.752) is also within normal values, averaging (9.775).
RVTY | WAT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 31 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 57 | |
SMR RATING 1..100 | 86 | 89 | |
PRICE GROWTH RATING 1..100 | 3 | 10 | |
P/E GROWTH RATING 1..100 | 8 | 2 | |
SEASONALITY SCORE 1..100 | 85 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RVTY's Valuation (79) in the Medical Specialties industry is in the same range as WAT (90). This means that RVTY’s stock grew similarly to WAT’s over the last 12 months.
WAT's Profit vs Risk Rating (57) in the Medical Specialties industry is somewhat better than the same rating for RVTY (100). This means that WAT’s stock grew somewhat faster than RVTY’s over the last 12 months.
RVTY's SMR Rating (86) in the Medical Specialties industry is in the same range as WAT (89). This means that RVTY’s stock grew similarly to WAT’s over the last 12 months.
RVTY's Price Growth Rating (3) in the Medical Specialties industry is in the same range as WAT (10). This means that RVTY’s stock grew similarly to WAT’s over the last 12 months.
WAT's P/E Growth Rating (2) in the Medical Specialties industry is in the same range as RVTY (8). This means that WAT’s stock grew similarly to RVTY’s over the last 12 months.
| RVTY | WAT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 77% | 1 day ago 62% |
| Stochastic ODDS (%) | 1 day ago 71% | 1 day ago 63% |
| Momentum ODDS (%) | 1 day ago 69% | 1 day ago 65% |
| MACD ODDS (%) | 1 day ago 69% | 1 day ago 62% |
| TrendWeek ODDS (%) | 1 day ago 66% | 1 day ago 64% |
| TrendMonth ODDS (%) | 1 day ago 66% | 1 day ago 64% |
| Advances ODDS (%) | 6 days ago 67% | 6 days ago 64% |
| Declines ODDS (%) | 1 day ago 67% | 1 day ago 62% |
| BollingerBands ODDS (%) | 1 day ago 69% | 1 day ago 66% |
| Aroon ODDS (%) | 1 day ago 67% | 1 day ago 57% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RVTY’s FA Score shows that 2 FA rating(s) are green while WAT’s FA Score has 2 green FA rating(s).
- RVTY’s FA Score: 2 green, 3 red.
- WAT’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RVTY’s TA Score shows that 3 TA indicator(s) are bullish while WAT’s TA Score has 4 bullish TA indicator(s).
- RVTY’s TA Score: 3 bullish, 5 bearish.
- WAT’s TA Score: 4 bullish, 4 bearish.
Price Growth
RVTY (@Medical Specialties) experienced а -5.48% price change this week, while WAT (@Medical Specialties) price change was -1.41% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.28%. For the same industry, the average monthly price growth was -6.26%, and the average quarterly price growth was +40.23%.
Reported Earning Dates
RVTY is expected to report earnings on Nov 03, 2026.
WAT is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Medical Specialties (-1.28% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
WAT and
Correlation & Price change
A.I.dvisor indicates that over the last year, WAT has been loosely correlated with A. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if WAT jumps, then A could also see price increases.
| Ticker / NAME | Correlation To WAT | 1D Price Change % | ||
|---|---|---|---|---|
| WAT | 100% | -2.85% | ||
| A - WAT | 65% Loosely correlated | -1.65% | ||
| RVTY - WAT | 60% Loosely correlated | -3.44% | ||
| BRKR - WAT | 58% Loosely correlated | -2.42% | ||
| TMO - WAT | 57% Loosely correlated | -2.06% | ||
| CRL - WAT | 57% Loosely correlated | -5.81% | ||
More | ||||